Cytokinetics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced that CEO Robert I. Blum will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The chat will be pre-recorded and available for on-demand viewing starting November 22, 2021, at 10:00 AM ET. It can be accessed through the Investors & Media section of Cytokinetics' website. The company focuses on innovative muscle activators and inhibitors to treat diseases affecting muscle performance, with ongoing Phase 3 trials for its candidates.

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33^rd Annual Virtual Healthcare Conference taking place November 30, 2021 to December 2, 2021.

The pre-recorded fireside chat will be available for on-demand viewing beginning November 22, 2021 at 10:00 AM ET. Interested parties may access it by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. A replay of the fireside chat will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing a U.S. NDA submission of omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The company has announced positive results from Cohorts 1 and 2 in REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics is conducting start-up activities for SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:
Cytokinetics
Joanna Siegall
Senior Manager, Corporate Communications, Investor Relations
(425) 314-1721

FAQ

When will Cytokinetics' CEO participate in the Piper Sandler conference?

Robert I. Blum, CEO of Cytokinetics, will participate in the fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare Conference, which takes place from November 30 to December 2, 2021.

How can I view the Cytokinetics fireside chat?

The pre-recorded fireside chat will be available for on-demand viewing starting November 22, 2021, at 10:00 AM ET on the Investors & Media section of Cytokinetics' website.

What is Cytokinetics focusing on in its research?

Cytokinetics is focused on developing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised.

What are the latest clinical trials Cytokinetics is conducting?

Cytokinetics is conducting Phase 3 trials for omecamtiv mecarbil in heart failure and aficamten for hypertrophic cardiomyopathies.

What is the significance of the GALACTIC-HF trial for Cytokinetics?

The GALACTIC-HF trial provided positive results for omecamtiv mecarbil, supporting Cytokinetics' upcoming U.S. NDA submission.